Clinical Trial Update: Investigation of the Safety, Tolerability and Potential Therapeutic Effects of JNJ-40411813 in Patients With Schizophrenia [Phase 2]

View source ↗

Summary

Phase 2 trial of JNJ-40411813 in schizophrenia has completed, examining safety, tolerability and potential therapeutic effects.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• JNJ-40411813

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Schizophrenia | Phase 2 | Status: COMPLETED